Cellular Therapy & Cord Blood Market Reviewed by Select Biosciences in Insightful Report Published at MarketPublishers.com

09 Aug 2013 • by Natalie Aster

LONDON – In 2013, the worldwide spending on the cellular therapy amounted to around USD 3.6 billion. The US is the biggest spender, accounting for over 80% of the total figure. It is followed by the EU.

The use of cord blood as a source of stem cells for cellular therapy tends to gain in importance. The application areas are constantly expanding both in adult and pediatric patient population. The number of the clinical trials related to the use of cord blood is also increasing, thus, supporting growth of the market.

In-demand research report “Cellular Therapy and Cord Blood 2013 Market Report” worked out by Select Biosciences Ltd. provides an in-depth analysis of the cellular therapy and the HSCT/cord blood market.

The report a comprehensive guide to the the cellular therapy and the cord blood market with a focus on the quantitative market metrics. It covers clinical trial trends and evolution of therapeutic areas; describes the actual state of various programmes within the preclinical; and uncovers essential data on the market performance including sales statistics. The study examines the key geographical markets, provides insights into the regulative landscape, uncovers details on the major market participants, and scrutinizes the key market segments. Moreover, the report discusses the key industry issues and outlines the top market opportunities.

Report Details:

Cellular Therapy and Cord Blood 2013 Market Report
Published: February, 2013
Pages: 172
Price: US$ 2,119.00

More In-Demand Market Research Reports by Select Biosciences Include:

More market research studies by the publisher can be found at Select Biosciences page.



The Market Publishers, Ltd.
Tanya Levdikova
Tel: +44 208 144 6009
Fax: +44 207 900 3970